Trial · NCT04200456
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50x10^9/L, for at Least 8 Out of 12 Weeks During the Last 12 Weeks | Placebo | 0 | Percentage of participants | ||
| Percentage of Participants With Durable Clinically Meaningful Platelet Response of ≥50x10^9/L, for at Least 8 Out of 12 Weeks During the Last 12 Weeks | Rozanolixizumab | 19.0 | Percentage of participants | ||
| Cumulative Number of Weeks With Clinically Meaningful Platelet Response of ≥50×10^9/L Over the 24-week Treatment Period | Placebo | 0.0 | Full Range 0 to 7 | Weeks | |
| Cumulative Number of Weeks With Clinically Meaningful Platelet Response of ≥50×10^9/L Over the 24-week Treatment Period | Rozanolixizumab | 3.0 | Full Range 0 to 24 | Weeks | |
| Time to First Clinically Meaningful Platelet Response (CMPR) of ≥50×10^9/L: Time From Starting Treatment to Achievement of First Response of ≥50×10^9/L | Placebo | 44.0 | 95% Confidence Interval 6.0 to NA | days | |
| Time to First Clinically Meaningful Platelet Response (CMPR) of ≥50×10^9/L: Time From Starting Treatment to Achievement of First Response of ≥50×10^9/L | Rozanolixizumab | 8.0 | 95% Confidence Interval 6.0 to NA | days | |
| Percentage of Participants With Clinically Meaningful Platelet Response of ≥50×10^9/L by Day 8 | Placebo | 16.7 | Percentage of participants | ||
| Percentage of Participants With Clinically Meaningful Platelet Response of ≥50×10^9/L by Day 8 | Rozanolixizumab | 52.4 | Percentage of participants | ||
Percentage of Participants With Response Defined as Platelet Count ≥30*10^9/L and at Least Doubling of Baseline, at Least 2 Separate Occasions at Two Adjacent Nominal Visits at Least 7 Days Apart, and Absence of Bleeding | Placebo | 8.3 | Percentage of participants | ||
Percentage of Participants With Response Defined as Platelet Count ≥30*10^9/L and at Least Doubling of Baseline, at Least 2 Separate Occasions at Two Adjacent Nominal Visits at Least 7 Days Apart, and Absence of Bleeding | Rozanolixizumab | 33.3 | Percentage of participants | ||
| Time to First Rescue Therapy | Placebo | 34.5 | 95% Confidence Interval 4.0 to NA | Days | |
| Time to First Rescue Therapy | Rozanolixizumab | NA | 95% Confidence Interval 23.0 to NA | Days | |
| Change From Baseline to Week 25 in Primary Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score | Placebo | 6.9 | Standard Deviation 13.8 | units on a scale | |
| Change From Baseline to Week 25 in Primary Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ) Symptoms Score | Rozanolixizumab | 5.5 | Standard Deviation 9.2 | units on a scale | |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | 75.0 | Percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rozanolixizumab | 85.7 | Percentage of participants | ||
| Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (ie, Study Discontinuation) | Placebo | 0 | Percentage of participants | ||
| Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (ie, Study Discontinuation) | Rozanolixizumab | 4.8 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04200456/results